Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda

Alisen Ayitewala, Fred Kyeyune, Pamela Ainembabazi, Eva Nabulime, Charles Drago Kato, Immaculate Nankya, Alisen Ayitewala, Fred Kyeyune, Pamela Ainembabazi, Eva Nabulime, Charles Drago Kato, Immaculate Nankya

Abstract

Background: Resistance to antiretroviral drugs is a major challenge among Human Immunodeficiency Virus (HIV) positive patients receiving antiretroviral therapy (ART). Mutations that arise as a result of this are diverse across the various drugs, drug classes, drug regimens and subtypes. In Uganda, there is a paucity of information on how these mutations differ among the different drug regimens and the predominant HIV-1 subtypes. The purpose of this study was to determine mutation profile differences between first-line drug regimens: TDF/3TC/EFV and AZT/3TC/EFV and HIV-1 subtypes: A and D in Uganda. The study also investigated the potential usage of rilpivirine, doravirine and etravirine in patients who failed treatment on efavirenz.

Methods: A retrospective study was conducted on 182 archived plasma samples obtained from patients who were experiencing virological failure between 2006 and 2017 at five Joint Clinical Research Center (JCRC) sites in Uganda. Sanger sequencing of the Reverse Transcriptase (RT) gene from codons 1-300 was done. Mutation scores were generated using the Stanford University HIV Drug Resistance Database. A Chi-square test was used to determine the association between drug resistance mutations (DRMs) and drug regimens or HIV-1 subtypes.

Results: The prevalence of DRMs was 84.6% among patients failing a first-line efavirenz (EFV)-based regimen. The most prevalent Nucleoside Reverse Transcriptase Inhibitor (NRTI) mutations were M184V/I (67.3%), K219/Q/E (22.6%) and K65R (21.1%). While K103N (50.8%) and G190A/S/E/G (29.1%) were the most prevalent Non-Nucleoside Reverse Transcriptase Inhibitor (NNTRI) mutations. As expected, discriminatory DRMs such as K65R, L74I, and Y115F were noted in Tenofovir (TDF) containing regimens while the Thymidine Analogue Mutations (TAMs) L210W and T215 mutations were in Zidovudine (AZT)-based regimens. No significant difference (p = 0.336) was found for overall DRMs between HIV-1 subtypes A and D. Among the patients who had resistance to EFV, 37 (23.6%) were susceptible to newer NNRTIs such as Rilpivirine and Etravirine.

Conclusion: Accumulation of DRMs between AZT/3TC/EFV and TDF/3TC/EFV is comparable but individual mutations that confer resistance to particular drugs should be considered at virological failure. Having either HIV-1 subtype A or D is not associated with the acquisition of DRMs, therefore HIV diversity should not determine the choice of treatment. Rilpivirine, etravirine and doravirine had minimal benefits for patients who failed on efavirenz.

Keywords: ART drug regimen; HIV drug resistance; HIV-1 subtype.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Prevalence of drug resistance mutations
Fig. 2
Fig. 2
Drug resistance mutation profiles between drug regimen. **Significant difference across drug regimens
Fig. 3
Fig. 3
Drug resistance mutation profiles among subtypes. **Significant difference across HIV-1 subtypes
Fig. 4
Fig. 4
Percentage reduction of efavirenz resistant for rilpivirine doravirine and etravirine

References

    1. UNAIDS. Fact sheets 2017. 2017.
    1. (UAC), Uganda AIDS Commission. The Uganda HIV and AIDS country progress report. 2016.
    1. Iyidogan P, Anderson KS. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses. 2014;6(10):4095–4139. doi: 10.3390/v6104095.
    1. Mwagomba B, Zachariah R, Massaquoi M, Misindi D, Manzi M, Myer L. Mortality reduction associated with HIV/AIDS care and antiretroviral treatment in rural Malawi: evidence from registers, coffin sales and funerals. PLoS ONE. 2010;5(5):e10452. doi: 10.1371/journal.pone.0010452.
    1. Reniers G, Araya T, Davey G, Nagelkerke N, Berhane Y, Coutinho R, Sanders EJ. Steep declines in population-level AIDS mortality following the introduction of antiretroviral therapy in Addis Ababa, Ethiopia. AIDS. 2009;23(4):511–518. doi: 10.1097/QAD.0b013e32832403d0.
    1. WHO . WHO HIV drug resistance report. Geneva: World Health Organization; 2012.
    1. Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, Lawn SD, Wood R. Treatment interruption in a primary care antiretroviral therapy program in South Africa: Cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr. 2010;55(3):e17–e23. doi: 10.1097/QAI.0b013e3181f275fd.
    1. Marcelin AG, Charpentier C, Wirden M, Landman R, Valantin MA, Simon A, Katlama C, Yeni P, Descamps D, Aubron-Olivier C, Calvez V. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. J Antimicrob Chemother. 2012;67(6):1475–1478. doi: 10.1093/jac/dks047.
    1. Luber AD. Genetic barriers to resistance and impact on clinical response. J Int AIDS Soc. 2005;7(3):69. doi: 10.1186/1758-2652-7-3-69.
    1. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. In: Program and abstracts of the 2nd IAS conference on HIV pathogenesis and treatment, Paris, France; 2003. Abstract 43.
    1. Gallant JE, Rodriguez AE, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. In: Program and abstracts of the 43rd annual interscience conference on antimicrobial agents and chemotherapy, September 1417; Chicago, Illinois; 2003. Abstract H-1722a.
    1. Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus study. In: Program and abstracts of the 11th conference on retroviruses and opportunistic infections, February, 2004; San Francisco, California; 2004. Abstract 52.
    1. Larder BA, Coates KE, Kemp SD. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol. 1991;65:5232–5236. doi: 10.1128/JVI.65.10.5232-5236.1991.
    1. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Brown AJ, Savara AV, Hazelwood JD, D’Aquila RT. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis. 2000;181:904–911. doi: 10.1086/315329.
    1. Eron JJ., Jr The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS. 1996;10(suppl 5):S11–S19. doi: 10.1097/00002030-199612005-00003.
    1. Melby T, Tortell S, Thorborn D, et al. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients on failing ABC/COM. In: Program and abstracts of the 8th conference on retroviruses and opportunistic infections, February 48, 2001, Chicago, Illinois; 2001. Abstract 448.
    1. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2006. AIDS. 2004;20:13–23. doi: 10.1097/01.aids.0000247564.73009.bc.
    1. Smith JD, Bruce CB, Featherstone AS, Downing RG, Biryahawaho B, Clegg JCS, et al. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1. AIDS Res Hum Retrovir. 1994;10:577–583. doi: 10.1089/aid.1994.10.577.
    1. Brennan CA, Lund JK, Golden A, Yamaguchi J, Vallari AS, Phillips JF, et al. Serologic and phylogenetic characterization of HIV-1 subtypes in Uganda. AIDS. 1997;11:1823–1832. doi: 10.1097/00002030-199715000-00006.
    1. Rayfield MA, Downing RG, Baggs J, Hu DJ, Pieniazek D, Luo CC, et al. A molecular epidemiologic survey of HIV in Uganda. AIDS. 1998;12:521–527. doi: 10.1097/00002030-199805000-00014.
    1. Kyeyune F, Nankya I, Metha S, Akao J, Ndashimye E, Tebit DM, Rodriguez B, Kityo C, Salata RA, Mugyenyi P, Arts EJ, the JCRC Drug Resistance Working Group Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. AIDS. 2013;27(12):1899–909. doi: 10.1097/QAD.0b013e3283610ec7.
    1. Martínez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev. 2008;10(4):212–223.
    1. Grossman ZE, Paxinos E, Averbuch D, et al. MutationD30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrobial Agents Chemother. 2004;48(6):2159–2165. doi: 10.1128/AAC.48.6.2159-2165.2004.
    1. Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, Sugiura W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01 AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr. 2003;33(3):336–342. doi: 10.1097/00126334-200307010-00007.
    1. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med. 2011;365(7):637–646. doi: 10.1056/NEJMra1004180.
    1. Kityo C, Thompson J, Nankya I, Hoppe A, Ndashimye E, Warambwa C, Mambule I, van Oosterhout JJ, Wools K, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS, Paton NI. HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in Sub-Saharan Africa. Europe Africa Research Network for Evaluation of Second-line therapy. J Acquir Immune Defic Syndr. 2017;75(2):45–54. doi: 10.1097/QAI.0000000000001285.
    1. Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, Wainberg MA. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis. 2009;200(8):1202–1206. doi: 10.1086/605894.
    1. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Karstaedt A, Charalambous S, Petzold M, Katzenstein D, Morris L. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. Aids. 2010;24:1679–1687. doi: 10.1097/QAD.0b013e32833a097b.
    1. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naïve patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009;14:523–531.
    1. Van der Van Zyl GU, Merwe L, Claassen M, Zeier M, Preiser W. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. J Med Virol. 2011;83:1764–1769. doi: 10.1002/jmv.22189.
    1. Consolidated guidelines for prevention and treatment of HIV in Uganda. (MOH), Ministry of Health. 2016.
    1. Myhre J, Sifris D. Wholesale price of HIV drugs. 2018.
    1. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, de Corte B, Vingerhoets J, Pauwels R, et al. Tmc125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:4680–4686. doi: 10.1128/AAC.48.12.4680-4686.2004.
    1. De Bethune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009) Antiviral Res. 2010;85:75–90. doi: 10.1016/j.antiviral.2009.09.008.
    1. Das K, Clark AD, Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Bethune MP, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wildtype and drug-resistant HIV-1 variants. J Med Chem. 2004;47:2550–2560. doi: 10.1021/jm030558s.
    1. Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, Koymans L, Vinkers M, Guillemont J, Pasquier E, Kukla M, Ludovici D, Andries K, de Bethune MP, Pauwels R, Das K, Clark AD, Jr, Frenkel YV, Hughes SH, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine) J Med Chem. 2005;48:1901–1909. doi: 10.1021/jm040840e.
    1. Thermo Fisher Scientific. GeneAmp PCR System 9700 Base Module. 2010. .
    1. Qiagen. QIAamp Viral RNA Mini Handbook. 2018. .
    1. Invitrogen. Invitrogen SYBR Safe DNA Gel Stain protocol. 2007. .
    1. Thermo Fisher Scientific. ExoSAP-IT PCR Product Cleanup Quick Reference. 2017. .
    1. Thermo Fisher Scientific. Applied Biosystems 3730/3730xl DNA Analyzers User Guide. 2010. .
    1. Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, Wynhoven B, Hall TA, Trevino C, Shafer RW, Harrigan PR. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. Clin Microbiol. 2012;50(6):1936–1942. doi: 10.1128/JCM.06689-11.
    1. Rhee SY, Grant PM, Tzou PL, Barrow G, Harrigan PR, Ioannidis JP, Shafer RW. A systematic review of the genetic mechanisms of dolutegravir resistance. J Antimicrob Chemother. 2019;74(11):3135–3149. doi: 10.1093/jac/dkz256.
    1. Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014;42(18):e144. doi: 10.1093/nar/gku739.
    1. IBM. IBM SPSS statistics V25.0 documentation. 2017. .
    1. Hamers RL, Oyomopito R, Kityo C, et al. Cohort profile: the PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance—HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol. 2012;41:43–54. doi: 10.1093/ije/dyq192.
    1. Manasa J, Lessells RJ, Skingsley A, et al. High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa. PLoS ONE. 2013;8:e72152. doi: 10.1371/journal.pone.0072152.
    1. von Braun A, Sekaggya-Wiltshire C, Scherrer AU, Magambo B, Kambugu A, Fehr J, Castelnuovo B. Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis. AIDS Res Ther. 2017;14:1. doi: 10.1186/s12981-016-0128-5.
    1. Miller V, Stark T, Loeliger AE, et al. The impact of the M184 V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med. 2002;3:135–145. doi: 10.1046/j.1468-1293.2002.00101.x.
    1. Averbuch D, Schapiro JM, Lanier ER, et al. Diminished selection for thymidine-analog mutations associated with the presence of M184 V in Ethiopian children infected with HIV subtype C receiving lamivudine containing therapy. Pediatr Infect Dis J. 2006;25:1049–1056. doi: 10.1097/01.inf.0000243211.36690.d5.
    1. Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, Wulfsohn M. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189(5):837–846. doi: 10.1086/381784.
    1. Menendez-Arias L. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 2008;134:124–146. doi: 10.1016/j.virusres.2007.12.015.
    1. Menéndez-Arias L. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res. 2013;98:93–120. doi: 10.1016/j.antiviral.2013.01.007.
    1. Venner CM, Nankya I, Kyeyune F, Demers K, Kwok C, Chen PL, Rwambuya S, Munjoma M, Chipato T, Byamugisha J, Van Der Pol B. Infecting HIV-1 subtype predicts disease progression in women of Sub-Saharan Africa. EBioMedicine. 2016;13:305–314. doi: 10.1016/j.ebiom.2016.10.014.
    1. Teeranaipong P, Sirivichayakul S, Mekprasan S, Ohata PJ, Avihingsanon A, Ruxrungtham K, Putcharoen O. Role of rilpivirine and etravirine in efavirenz and nevirapine-based regimens failure in a resource-limited country: a cross-sectional study. PLoS ONE. 2016;11(4):e0154221. doi: 10.1371/journal.pone.0154221.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit